ADMA Biologics, Inc. or Evotec SE: Who Invests More in Innovation?

Evotec SE outpaces ADMA in R&D investment by 360%.

__timestampADMA Biologics, Inc.Evotec SE
Wednesday, January 1, 2014951701412404000
Thursday, January 1, 2015701594618343000
Friday, January 1, 2016768823818108000
Sunday, January 1, 2017622958717614000
Monday, January 1, 2018392612035619000
Tuesday, January 1, 2019234384858432000
Wednesday, January 1, 2020590701363945000
Friday, January 1, 2021364606072200000
Saturday, January 1, 2022361376476642000
Sunday, January 1, 2023330000057519000
Loading chart...

Unveiling the hidden dimensions of data

Innovation Investment: A Tale of Two Companies

In the competitive world of biotechnology, innovation is key. ADMA Biologics, Inc. and Evotec SE are two companies that have consistently invested in research and development (R&D) over the past decade. From 2014 to 2023, Evotec SE has shown a remarkable commitment to innovation, with R&D expenses growing by over 360%, peaking at approximately €76 million in 2022. In contrast, ADMA Biologics, Inc. has seen a decline in R&D spending, dropping by about 65% from its 2014 levels. This divergence highlights Evotec SE's strategic focus on innovation, positioning it as a leader in the biotech sector. As the industry evolves, the ability to invest in R&D will likely determine the future leaders in biotechnology.

The Innovation Race: Who Leads in Biotech?

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025